# Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

> **NCT05219617** · PHASE3 · RECRUITING · sponsor: **SK Life Science, Inc.** · enrollment: 252 (estimated)

## Conditions studied

- Seizures
- Lennox Gastaut Syndrome

## Interventions

- **DRUG:** Carisbamate

## Key facts

- **NCT ID:** NCT05219617
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-28
- **Primary completion:** 2027-02
- **Final completion:** 2028-12
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05219617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05219617, "Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05219617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*